Tareg Indications/Uses

Hypertension: Treatment of hypertension in adults and in children and adolescents 6-18 years of age.
Heart failure: Treatment of heart failure (NYHA class II-IV) in adult patients receiving standard therapy such as diuretics, digitalis and either angiotensin-converting enzyme (ACE) inhibitors or beta-blockers but not both; presence of all these standard therapies is not mandatory.
Valsartan improves morbidity in these patients, primarily via reduction in hospitalization for heart failure. Valsartan also slows the progression of heart failure, improves NYHA functional class, ejection fraction and signs and symptoms of heart failure and improves quality of life versus placebo (see Pharmacology: Pharmacodynamics under Actions).
Post-myocardial infarction: Valsartan is indicated to improve survival following myocardial infarction in clinically stable adult patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see Pharmacology: Pharmacodynamics under Actions).
Hypertensive adult patients with Impaired Glucose Tolerance at cardiovascular risk: Valsartan is indicated in addition to lifestyle modifications to delay the progression to type 2 diabetes in hypertensive adult patients with impaired glucose tolerance at cardiovascular risk (see Pharmacology: Pharmacodynamics under Actions).